Daclatasvir: A Review of Preclinical and Clinical Pharmacokinetics-Reference-Cited by-同舟云学术

Daclatasvir: A Review of Preclinical and Clinical Pharmacokinetics

Published:2018-01-20 Issue:8 Volume:57 Page:911-928
ISSN:0312-5963
Container-title:Clinical Pharmacokinetics
language:en
Short-container-title:Clin Pharmacokinet

Author:

Gandhi Yash,Eley Timothy,Fura Aberra,Li Wenying,Bertz Richard J.,Garimella Tushar^ORCID

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Pharmacology

Link

http://link.springer.com/article/10.1007/s40262-017-0624-3/fulltext.html

Reference37 articles.

1. Polaris Observatory HCV Collaborators. Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study. Lancet Gastroenterol Hepatol. 2017;2:161–76.

2. National Institutes of Health. National Institutes of Health Consensus Development Conference Statement: management of hepatitis C: June 10–12, 2002. Hepatology. 2002;36(5 Suppl. 1):S3–20.

3. Rodriguez-Luna H, Douglas DD. Natural history of hepatitis C following liver transplantation. Curr Opin Infect Dis. 2004;17:363–71.

4. Global surveillance and control of hepatitis C. Report of a WHO consultation organized in collaboration with the Viral Hepatitis Prevention Board, Antwerp, Belgium. J Viral Hepat. 1999;6:35–47.

5. Yoshizawa H. Hepatocellular carcinoma associated with hepatitis C virus infection in Japan: projection to other countries in the foreseeable future. Oncology. 2002;62(Suppl. 1):8–17.

Cited by 37 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Why Certain Repurposed Drugs Are Unlikely to Be Effective Antivirals to Treat SARS-CoV-2 Infections;Viruses;2024-04-22

2. Antiviral drugs prolong survival in murine recessive dystrophic epidermolysis bullosa;EMBO Molecular Medicine;2024-03-10

3. The Role of CYPs and Transporters in the Biotransformation and Transport of the Anti-hepatitis C Antiviral Agents Asunaprevir, Daclatasvir, and Beclabuvir: Impact of Liver Disease, Race and Drug-drug Interactions on Safety and Efficacy;Current Drug Metabolism;2024-02

4. A Synopsis of Hepatitis C Virus Treatments and Future Perspectives;Current Issues in Molecular Biology;2023-10-11

5. Mechanisms and Clinical Significance of Pharmacokinetic Drug Interactions Mediated by FDA and EMA-approved Hepatitis C Direct-Acting Antiviral Agents;Clinical Pharmacokinetics;2023-09-20